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ABSTRACT: Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer’s disease (AD). Food and Drug
Administration–approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier. In this
short review, we discuss the involvement of TNF-α in AD, challenges associated with the development of existing biologic TNF-α inhibitors for
AD, and potential therapeutic strategies for targeting TNF-α for AD therapy.
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Introduction

Alzheimer’s disease (AD) is the leading cause of dementia
worldwide and represents one of the most serious health issues
for the elderly. An estimated 5.4 million Americans have AD,
and this number is expected to triple in 2050 due to lack of
medical breakthroughs to stop, prevent, or slow the disease.1
Over the years, research efforts have focused extensively on
delineating the mechanisms and identifying targets involved in
AD pathogenesis; however, to date, no disease-modifying therapy has been clinically approved for AD.
The 2 major neuropathological hallmarks of AD are extracellular deposition of amyloid beta (Aβ)–containing senile
plaques and intracellular tau-containing neurofibrillary tangles (NFTs) in the brain.2 Aβ plaque formation is considered
relatively specific to AD pathology; however, NFTs are found
associated with other disorders as well.3 Aβ plaque formation
involves a cascade of events beginning with the sequential
cleavage of the amyloid precursor protein (APP), a large
transmembrane protein, by proteolytic enzymes β-secretase
and γ-secretase. Cleavage by γ-secretase releases Aβ, peptides
which are usually composed of 40 to 42 amino acid residues,
into the extracellular space where they aggregate into oligomers, β-sheet–structured fibrils, followed by clumping into Aβ
plaques.4 Some studies suggest that Aβ pathology more
closely reflects the preclinical (asymptomatic) stage of AD,
whereas accumulation of tau tangles more closely reflects the
onset of clinical symptoms in AD.5 Among the numerous
targets explored to treat AD, anti-Aβ approaches directed
toward removal of Aβ and/or decreasing its production (eg,
inhibition of γ-secretase, active immunotherapy, and anti-Aβ
antibodies) have shown promising results in animal models of
AD6–8 and have been at the forefront of AD research. Most
of the studies investigating the effects of anti-Aβ approaches
have had limited success in mid- to late-stage clinical development and have failed to reach primary clinical end points.9
A recent study investigated the effect of a selective tau

Declaration of Conflicting Interests: The author(s) declared no potential
conflicts of interest with respect to the research, authorship, and/or publication of this
article.
Corresponding Author: Rachita K Sumbria, Department of Biopharmaceutical
Sciences, School of Pharmacy, Keck Graduate Institute, Claremont, CA 91711, USA. Email:
rsumbria@kgi.edu

aggregation inhibitor in patients with mild-to-moderate AD.
This anti-tau approach, however, failed to reach primary outcome measures.10
More recent research has pivoted focus to cytokine-mediated
neuroinflammation as a major contributor to the development of
AD, and evidence suggests that inflammation promotes pathological processes that lead to AD.11–13 Among the cytokines
involved in neuroinflammation, tumor necrosis factor α (TNFα) is the most studied and plays an essential role in the cytokine
cascade during an inflammatory response. Although the levels of
TNF-α in the periphery and central nervous system (CNS) of
healthy adults are maintained at very low levels, the levels of this
cytokine are significantly elevated in blood14 and CNS12 of
patients with AD, and many clinical and animal studies have
demonstrated a link between excess TNF-α levels in the brain
and AD.15 Here, we focus on the involvement of TNF-α in AD,
challenges associated with the development of existing biologic
TNF-α inhibitors (TNFIs) for AD, and potential therapeutic
strategies for targeting TNF-α for AD therapy.

TNF-α and TNF-α Receptors

TNF-α, first recognized for its antitumor activity,16 is one of the
main inflammatory cytokines involved in initiating and propagating an inflammatory response. TNF-α is a monomeric
(17 kDa) nonglycosylated type 2 transmembrane protein that
belongs to a superfamily of ligand/receptor proteins called
the TNF/TNF receptor (TNF/TNFR) superfamily proteins.
TNF-α is inserted into the membrane as a homotrimer which is
then cleaved into a 51-kDa soluble trimer via proteolytic cleavage by the TNF-α–converting enzyme.17 In the central nervous
system, TNF-α can be synthesized in the brain by microglia,18
neurons,19 and astrocytes.20
TNF-α binds to 2 receptor subtypes, TNFR1 (p55-R) and
TNFR2 (p75-R), each having distinct signaling pathways
differentiated by the presence of an intracellular death domain
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(DD).21 TNFR1, which contains the DD, is ubiquitously
expressed in various cell types and is activated through either
soluble TNF-α (sTNF-α) or membrane TNF-α (mTNF-α).22
TNFR1, once activated, is involved in divergent effects including cell proliferation, activation, antiviral activity, and primarily
in TNF-α–mediated apoptosis and cytotoxicity. TNFR2 has a
higher affinity for TNF-α, is activated preferentially by
mTNF-α, and is primarily expressed at low levels by cells of
the immune system and endothelial cells.22 TNFR2 lacks the
DD and can trigger signaling cascades that activate proinflammatory and pro-survival pathways through the activation of the cellular inhibitor of apoptosis proteins 1 and 2,
nuclear factor κB, and phosphatidylinositol 3-kinase–
dependent signaling pathways.23 Some studies also report an
indirect role of TNFR2 in TNF-α–mediated cytotoxicity via
the enhancement of TNFR1-mediated cytotoxicity, but no
induction of cytotoxicity by TNFR2 alone.24 Overall, the
general consensus is that TNFR1 exerts pro-apoptotic functions, whereas TNFR2 typically promotes cell survival and
proliferation.23

TNF-α Involvement in AD

The role of TNF-α in the pathophysiology of AD has been
examined both in clinical and animal studies. One of the earliest evidence suggesting the involvement of TNF-α in AD
pathophysiology was its presence around the Aβ plaque in
postmortem human AD brains.25 Following studies in human
AD brains showed that TNFR1 signaling is required for Aβinduced neuronal death, and although TNFR1 protein levels
are significantly greater in AD brains compared with nondemented brains, TNFR2 protein levels are lower.26 Furthermore,
an increase in the binding affinity of TNF-α to TNFR1, but a
decrease in binding affinity to TNFR2, was observed.26 Genetic
association studies showed that chromosome 12p region
encoding for the TNFR1 gene and the chromosome 1p region
encoding for the TNFR2 gene are associated with late-onset
AD.27 The role of TNF-α in AD pathology was further suggested by studies in which significant elevation of TNF-α levels in the cerebrospinal fluid (CSF)28 and serum29,30 of patients
with AD correlated with disease progression.30
The reported clinical findings regarding the role of TNFα in AD pathology are consistent with observations made in
mouse models of AD. Elevated TNF-α levels were observed
in the brain tissues of AD transgenic mice.31 Furthermore,
elevated TNF-α levels were associated with intraneuronal
Aβ immunoreactivity in the entorhinal cortex, and these
elevated TNF-α levels correlated with cognitive deficits in
AD mice.32 The role of TNF-α signaling in abnormal APP
processing, Aβ plaque accumulation, tau-related pathology,
and cell death has also been reported. Deletion of TNFR1 in
AD transgenic mice lowered Aβ formation, Aβ plaque burden, β-secretase 1 (BACE1) expression, and cognitive deficits.33 However, ablation of both TNFR1 and TNFR2
exacerbated Aβ and tau pathology due to aggravation of
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Figure 1. Central role of TNF-α in AD pathophysiology. Elevated TNF-α
levels in AD may enhance Aβ production, decrease Aβ clearance,
increase neuronal loss and cell death, and are implicated in cognitive
decline in AD. Aβ indicates amyloid beta; AD, Alzheimer’s disease;
TNF-α, tumor necrosis factor α.

TNFR1-mediated AD pathology resulting from silencing of
TNFR2.34 Furthermore, genetic inactivation of TNFR1
signaling in AD transgenic mice prevented intraneuronal
accumulation of Aβ,35 whereas genetic deletion of TNFR2
exacerbated AD pathology in a transgenic mouse model of
AD.36 In AD transgenic mice, TNF-α increased Aβ production through upregulation of both β-secretase expression37
and γ-secretase activity,38 and chronic neuronal TNF-α
expression resulted in extensive neuronal cell death.19 Excess
TNF-α levels in the brain can disrupt clearance of Aβ by
inhibiting microglial clearance of Aβ,39 cause synaptic dysfunction,40 and accelerate disease progression and cognitive
decline.41 Overall, TNF-α–driven processes are involved at
multiple stages of AD pathophysiology and disease progression (Figure 1).

Targeting TNF-α in AD

The most potent TNFIs are biologic drugs that are Food
and Drug Administration (FDA) approved for the treatment
of peripheral inflammatory conditions including Crohn disease, rheumatoid arthritis, and psoriatic arthritis. These biologic TNFIs include TNF-α–specific monoclonal antibodies
(MAbs) (infliximab, adalimumab, golimumab, and certolizumab), and recombinant fusion proteins (etanercept).15 TNFα–specific MAbs bind to either mTNF-α or sTNF-α thus
preventing TNF-α signaling mediated by both TNFRs.
However, recombinant fusion protein TNFI (etanercept) is
comprised of the extracellular domain (ECD) of the TNFR2
fused to the c-terminal of the Fc domain of human IgG1. The
fusion protein also binds to both mTNF-α and sTNF-α with
high affinity preventing TNF-α signaling mediated by both
TNFRs.23
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Table 1. Summary of studies focusing on neutralization of brain TNF-α with biologic TNFIs in AD.
Biologic TNFI

Species

Route of administration

Therapeutic effect

Etanercept

Human

Perispinal

Cognitive improvement45

Infliximab

Human

Intrathecal

Cognitive improvement, change in blood,
and CSF Aβ and tau47

Mouse

Intracerebroventricular

Reduction in Aβ pathology, tau
phosphorylation, and cognitive deficits42–44

Mouse

Intrahippocampal

Reduction in Aβ pathology35

Recombinant dominant negative TNFI

Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; TNF-α, tumor necrosis factor α; TNFI, TNF-α inhibitor.

The protective effects of TNF-α inhibition using these biologic TNFIs have been demonstrated both in clinical and
experimental AD (Table 1). Inhibition of sTNF-α signaling by
intracerebral infusion of a dominant negative TNFI prevented
preplaque Aβ-associated pathology in a transgenic mouse
model of AD.35 Intracerebroventricular injection of the antiTNF-α MAb, infliximab, reduced TNF-α levels, Aβ plaques
and tau-phosphorylation,42 and cognitive deficits43,44 in mouse
models of AD. In a small open-label 6-month study in humans,
perispinal etanercept administration (dose range: 25-50 mg per
week) resulted in significant improvement in 3 standard measures of cognition: the AD Assessment Scale-Cognitive Subscale,
the Severe Impairment Battery, and the Mini-Mental State
Examination in patients with AD.45 These observed clinical
improvements are hypothesized to be due to rapid penetration
of etanercept into the CSF following perispinal administration
and mediated by nonsynaptic signal transduction mechanisms
of etanercept. However, in a recent study, perispinal injection of
etanercept resulted in perispinal drug accumulation, but consistent intracranial delivery of the drug was not observed.46 In a
recent case report, intrathecal administration of infliximab
resulted in rapid cognitive improvement in a female patient
with AD,47 and larger controlled trials are warranted.
Collectively, both clinical and preclinical evidence underscore
the therapeutic potential of biologic TNFIs for AD therapy.
One hindrance to the further development of the FDAapproved biologic TNFIs for AD is their limited blood-brain
barrier (BBB) penetration,48 and invasive delivery approaches
may not be practical or safe for chronic dosing for AD. Recently,
modulation of peripheral TNF-α activity by biologic TNFIs
has shown promise in transgenic mouse models of AD49; however, in a randomized double-blind phase 2 clinical trial, weekly
subcutaneous injections of etanercept did not improve cognition, global function, or behavior in a small group of subjects
with mild-to-moderate AD dementia.50 Further studies will be
needed to determine whether peripheral modulation of TNFα offers clinical improvement in AD.
Biologic drugs such as etanercept, ECD of the TNFR2, can
be reengineered to enable BBB penetration by fusion of the
biologic drug to a BBB molecular Trojan horse (MTH).51 A
BBB MTH is an endogenous peptide or peptidomimetic monoclonal antibody that undergoes receptor-mediated transport

across the BBB via endogenous peptide receptors, such as the
transferrin receptor (TfR) or the insulin receptor. This binding
triggers receptor-mediated transport of the MAb across the
BBB, which ferries the biologic drug into the brain.52 One such
BBB-penetrating TNFR, specific for the mouse, has been
engineered and tested in mouse models of neurological diseases
(Figure 2). The amino terminus of the human TNFR2 ECD is
fused to the carboxyl terminal of the heavy chain of the chimeric TfRMAb to engineer a fusion protein designated as
cTfRMAb-TNFR.53 This orientation frees the amino terminus of the cTfRMAb that is involved in binding to the BBB
TfR and places the TNFR ECD in a dimeric configuration.
Because both human and mouse monomeric TNF-α share
high amino acid identity, and the human TNFR binds mouse
TNF-α with high affinity,54 the cTfRMAb-TNFR fusion protein involves the human TNFR and not the mouse TNFR. The
cTfRMAb-TNFR fusion protein binds to both the mouse TfR
and TNF-α with high affinity evident from the low binding
constants (Kd = 2.6 ± 0.3 nM for mouse TfR and 96 ± 34 pM for
TNF-α). The cTfRMAb-TNFR is thus a bifunctional molecule that allows (a) rapid noninvasive transvascular delivery of
the TNFR across the BBB using a receptor-mediated transcytosis approach and (b) once in the brain, the TNFR can sequester excess TNF-α. A complete pharmacokinetic analysis of this
BBB-penetrating biologic TNFI, the cTfRMAb-TNFR fusion
protein, showed that systemic routes (intraperitoneal, subcutaneous, or intravenous) of administration result in brain concentrations of the cTfRMAb-TNFR fusion protein that are
20-fold to 50-fold greater than the concentration of TNF-α in
pathologic conditions of the brain.55 The intravenous route of
administration is preferred for acute neurological conditions,
such as ischemic stroke, whereas the intraperitoneal or subcutaneous routes of administration are more practical for dosing
during chronic conditions including AD. The cTfRMAbTNFR fusion protein was found to be protective in both acute
(ischemic stroke) and chronic (Parkinson disease) mouse models of neurological diseases56–58 and is currently being investigated in a mouse model of AD.
For use in humans, a fusion protein of the ECD of the TNFR2
and a chimeric or humanized antibody against the human insulin
receptor (HIRMAb), designated as the HIRMAb-TNFR fusion
protein, has been engineered.48 The HIRMAb is the most potent
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Figure 2. Schematic of the molecular Trojan horse (MTH) technology to ferry biologic TNF-α inhibitors (TNFIs) into the brain. The TNFI of interest in the
figure is a tumor necrosis factor α receptor (TNFR). A fusion protein of TNFR and a blood-brain barrier (BBB) MTH, such as the chimeric monoclonal
antibody against the mouse transferrin receptor (cTfRMAb), can be engineered and this is designated as cTfRMAb-TNFR. Following systemic injection,
the cTfRMAb-TNFR fusion protein binds to the BBB transferrin receptor (TfR)1 and is transported across the BBB from blood to brain via the BBB TfR that
undergoes receptor-mediated transcytosis. 2 Once in the brain, the TNFR domain of the fusion protein can sequester excess TNF-α in the brain.3

MTH engineered for the human brain and cross-reacts with the
insulin receptor of the Old World primates. In rhesus monkeys,
the brain uptake of a 0.2 mg/kg dose of the HIRMAb-TNFR
fusion protein after intravenous injection was 3 ± 0.1% ID/100 g
brain compared with the brain uptake of the TNFR:Fc fusion
protein which was 0.23 ± 0.06% ID/100 g brain. Furthermore,
chronic administration of a high dose (20 mg/kg) of a
HIRMAb-based fusion protein was found to be safe in rhesus
monkeys.59

Conclusions

A plethora of clinical and animal studies strongly suggest an
involvement of TNF-α in the pathophysiology of AD. The
FDA-approved biologic TNFIs are thus a potential treatment
for AD; however, these large molecules have limited BBB penetration. Clinical studies using the perispinal route of administration for biologic TNFIs have shown encouraging results in
small open-label trials; however, larger controlled trials are
required to confirm these results. Another approach currently
under investigation is to target peripheral TNF-α rather than
brain TNF-α. However, this approach has not shown any cognitive improvement in a clinical setting so far, and further studies are required to determine the effect of peripheral TNF-α
modulation on AD pathology. Novel drug delivery strategies,
such as the MTH technology, enable noninvasive delivery of
biologic TNFIs to the brain and target both peripheral and
brain TNF-α. Considering the multifactorial role of brain
TNF-α in AD pathophysiology, such noninvasive drug delivery strategies may be a reasonable approach to deliver biologic
TNFIs to the brain for AD treatment.
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